Roche Holding AG (FRA:RHO) Interest Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RHO Roche Holding AG FRA:RHO
74 GF Score
Price €387.60
GF Value €291.08
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Interest Paid?

Interest Paid only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:RHO
74GF Score
Roche Holding AG FRA:RHO
Interest Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roche Holding AG (FRA:RHO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of €387.60 is trading 33.2% above its estimated GF Value™ of €291.08. GuruFocus considers Roche Holding AG to be Significantly Overvalued.

Key valuation signals for FRA:RHO:

  • Interest Paid:
  • GF Value™: €291.08 vs. price of €387.60 (33.2% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the FRA:RHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche Holding AG is a Swiss healthcare company operating through two divisions: Pharmaceuticals and Diagnostics. The pharmaceuticals business develops and markets prescription medicines, with major franchises in oncology, immunology, neuroscience, infectious diseases, and ophthalmology, including therapies such as Rituxan/MabThera, Herceptin, Avastin, Ocrevus, Hemlibra, and Tecentriq. The diagnostics division supplies in vitro tests, instruments, and reagents for centralized laboratories, point-of-care testing, molecular diagnostics, tissue diagnostics, and diabetes care. Roche sells to hospitals, clinics, laboratories, physicians, and healthcare systems worldwide, with significant revenue in the United States, Europe, Japan, and emerging markets. Revenue comes primarily from product sales of pharmaceuticals and diagnostic tests, supplemented by licensing and collaboration income. The company invests heavily in research and development and has a controlling interest in Chugai Pharmaceutical of Japan.
74GF Score

Get the complete analysis for FRA:RHO

Interest Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€387.60
Price
€291.08
GF Value